Company / CIK 0001200375
CODEXIS, INC.
- Ticker
- CDXS
- Size, estimated from filings
- Micro cap (under $300M)
- Insiders on file
- 13
- Federal contracts on record
- none matched
- Lobbying filings on record
- none matched
- SEC filings
- EDGAR ↗
- Latest trade on record
- October 12, 2026
CODEXIS, INC. (CDXS) has 13 insiders on file who disclosed 13 transactions in the last 12 months (0 open-market buys, 4 sales, about $30K at reported prices). No federal contract award that started in the last 180 days was found for a recipient with exactly this name; no lobbying filing names it as client this year.
CODEXIS, INC. in charts
Who is trading this stock
Which people account for the buying and selling over the last 12 months?
4 people account for the disclosed buying and selling in CODEXIS, INC. over the last 12 months; the most active is MOORE ALISON with $9K.
Insiders
| Name | Role | Rows | Bought | Sold | Last filed |
|---|---|---|---|---|---|
| Erbez Georgia | See Remarks | 1 | 0 | 1 | October 14, 2026 |
| MOORE ALISON | President and CEO | 1 | 0 | 1 | October 14, 2026 |
| PARKER H STEWART | Director | 1 | 0 | 0 | June 18, 2026 |
| Collins Cynthia | Director | 1 | 0 | 0 | June 18, 2026 |
| Richards Christos | Director | 1 | 0 | 0 | June 18, 2026 |
| Smith David V | Director | 1 | 0 | 0 | June 18, 2026 |
| Singhvi Rahul | Director | 1 | 0 | 0 | June 18, 2026 |
| Martinborough Esther | Director | 1 | 0 | 0 | June 18, 2026 |
| DILLY STEPHEN GEORGE | Director | 1 | 0 | 0 | June 18, 2026 |
| De Vre Raymond | Director | 2 | 0 | 1 | June 18, 2026 |
| Lutz Stefan | Chief Scientific Officer | 2 | 0 | 1 | February 25, 2026 |
| Ispagnac Participacoes Ltda. | Insider | 1 | 0 | 0 | June 3, 2011 |
| Equilon Enterprises LLC | Insider | 6 | 0 | 0 | April 29, 2010 |
Rows are this company's Form 4 rows for each person. "Bought" and "sold" count open-market purchases (code P) and sales only. More in insider buying and insider selling.
Insider transactions
| Filer | Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MOORE ALISON | CDXS | Sell S | October 12, 2026 | October 14, 2026 | 2d | 6,335 | $1 | $8,619 | Form 4 ↗ | ||
| Erbez Georgia | CDXS | Sell S | October 12, 2026 | October 14, 2026 | 2d | 6,335 | $1 | $8,619 | Form 4 ↗ | ||
| De Vre Raymond | CDXS | Other A | June 17, 2026 | June 18, 2026 | 1d | 66,350 | — | — | derivative | Form 4 ↗ | |
| DILLY STEPHEN GEORGE | CDXS | Other A | June 17, 2026 | June 18, 2026 | 1d | 66,350 | — | — | derivative | Form 4 ↗ | |
| Martinborough Esther | CDXS | Other A | June 17, 2026 | June 18, 2026 | 1d | 66,350 | — | — | derivative | Form 4 ↗ | |
| Singhvi Rahul | CDXS | Other A | June 17, 2026 | June 18, 2026 | 1d | 66,350 | — | — | derivative | Form 4 ↗ | |
| Smith David V | CDXS | Other A | June 17, 2026 | June 18, 2026 | 1d | 66,350 | — | — | derivative | Form 4 ↗ | |
| Richards Christos | CDXS | Other A | June 17, 2026 | June 18, 2026 | 1d | 66,350 | — | — | derivative | Form 4 ↗ | |
| Collins Cynthia | CDXS | Other A | June 17, 2026 | June 18, 2026 | 1d | 66,350 | — | — | derivative | Form 4 ↗ | |
| PARKER H STEWART | CDXS | Other A | June 17, 2026 | June 18, 2026 | 1d | 66,350 | — | — | derivative | Form 4 ↗ | |
| De Vre Raymond | CDXS | Sell S | June 11, 2026 | June 11, 2026 | 0d | 2,605 | $2 | $6,174 | Form 4 ↗ | ||
| Lutz Stefan | CDXS | Other A | February 23, 2026 | February 25, 2026 | 2d | 316,100 | — | — | derivative | Form 4 ↗ | |
| Lutz Stefan | CDXS | Sell S | February 24, 2026 | February 25, 2026 | 1d | 5,862 | $1 | $6,641 | Form 4 ↗ | ||
| Ispagnac Participacoes Ltda. | CDXS | Other J | June 1, 2011 | June 3, 2011 | 2d | 5,573,319 | — | — | Form 4 ↗ | ||
| Equilon Enterprises LLC | CDXS | Exchange C | April 27, 2010 | April 29, 2010 | 2d | 2,373,415 | — | — | indirectderivative | Form 4 ↗ | |
| Equilon Enterprises LLC | CDXS | Exchange C | April 27, 2010 | April 29, 2010 | 2d | 2,410,412 | — | — | indirectderivative | Form 4 ↗ | |
| Equilon Enterprises LLC | CDXS | Exchange C | April 27, 2010 | April 29, 2010 | 2d | 789,492 | — | — | indirectderivative | Form 4 ↗ | |
| Equilon Enterprises LLC | CDXS | Exchange C | April 27, 2010 | April 29, 2010 | 2d | 2,373,415 | — | — | indirect | Form 4 ↗ | |
| Equilon Enterprises LLC | CDXS | Exchange C | April 27, 2010 | April 29, 2010 | 2d | 2,410,412 | — | — | indirect | Form 4 ↗ | |
| Equilon Enterprises LLC | CDXS | Exchange C | April 27, 2010 | April 29, 2010 | 2d | 789,492 | — | — | indirect | Form 4 ↗ |
Federal contracts (USAspending, awards started in the last 180 days)
No contract award starting in the last 180 days was found for a recipient named exactly "CODEXIS, INC.". Subsidiaries and differently-spelled recipients are not matched — search contracts.
Lobbying (Senate LDA, as client)
No LDA filing posted since October 2025 names "CODEXIS, INC." as the client. Filings under a subsidiary or trade-association name are not matched — search lobbying.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 14 | 20 | April 29, 2010 | October 14, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Insiders and their transactions come from SEC EDGAR Form 4 filings for this issuer. Contracts and lobbying are matched by exact normalized name (suffixes like Inc./Corp. ignored) to USAspending recipients and LDA clients — a conservative match that misses subsidiaries on purpose. See methodology and corrections.
Not investment advice. Public records shown as filed; no recommendation is made or implied.